2. Search Result
Search Result
Pathways Recommended: Protein Tyrosine Kinase/RTK
Results for "

sphingosine kinases

" in MedChemExpress (MCE) Product Catalog:

59

Inhibitors & Agonists

1

Fluorescent Dyes

6

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19989
    MK-571
    Maximum Cited Publications
    33 Publications Verification

    L-660711

    		 P-glycoprotein LPL Receptor Leukotriene Receptor Inflammation/Immunology
    MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
    MK-571
  • HY-101047
    D-erythro-Sphingosine
    4 Publications Verification

    Erythrosphingosine; erythro-C18-sphingosine; trans-4-Sphingenine

    		 PKC Phosphatase Endogenous Metabolite Cancer
    D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator .
    D-erythro-Sphingosine
  • HY-15425
    PF-543
    20+ Cited Publications

    sphingosine Kinase 1 Inhibitor II

    		 SphK LPL Receptor Apoptosis Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    PF-543 (Sphingosine Kinase 1 Inhibitor II) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 is >100-fold selectivity for SPHK1 over SPHK2. PF-543 is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 induces apoptosis, necrosis, and autophagy .
    PF-543
  • HY-19989A
    MK-571 sodium
    Maximum Cited Publications
    33 Publications Verification

    L-660711 sodium

    		 P-glycoprotein LPL Receptor Leukotriene Receptor Inflammation/Immunology
    MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
    MK-571 sodium
  • HY-16015
    Opaganib
    5+ Cited Publications

    ABC294640

    		 SphK Cancer
    Opaganib (ABC294640) is a selective, competitive sphingosine kinase 2 (SK2) inhibitor with Ki of 9.8 μM.
    Opaganib
  • HY-13822
    SKI II
    5+ Cited Publications

    		 SphK Wnt Apoptosis Cancer
    SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC50 values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation .
    SKI II
  • HY-15425A
    PF-543 Citrate
    20+ Cited Publications

    sphingosine Kinase 1 Inhibitor II Citrate

    		 SphK LPL Receptor Apoptosis Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 Citrate is >100-fold selectivity for SPHK1 over SPHK2. PF-543 Citrate is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 Citrate induces apoptosis, necrosis, and autophagy .
    PF-543 Citrate
  • HY-16734A
    Amiselimod hydrochloride

    MT-1303 hydrochloride

    		 LPL Receptor Cardiovascular Disease Inflammation/Immunology
    Amiselimod (MT-1303) hydrochloride is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod hydrochloride is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod hydrochloride inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod hydrochloride inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimod hydrochloride is promising for research of autoimmune diseases .
    Amiselimod hydrochloride
  • HY-100008
    Peretinoin
    5+ Cited Publications

    NIK333

    		 RAR/RXR SphK Autophagy HCV Infection Cancer
    Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1 . Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression . Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM .
    Peretinoin
  • HY-108491
    N,N-Dimethylsphingosine
    1 Publications Verification

    		 SphK Apoptosis Cancer
    N,N-Dimethylsphingosine is a sphingosine kinase inhibitor. N,N-Dimethylsphingosine binds competitively to sphingosine kinase and blocks the conversion of sphingosine to sphingosine-1-phosphate. N,N-Dimethylsphingosine inhibits sphingosine-1-phosphate release and aggregation of platelets, and also exerts pro-apoptotic effects by resetting ceramide/sphingosine-1-phosphate homeostasis. N,N-Dimethylsphingosine can be used in cancer-related research .
    N,N-Dimethylsphingosine
  • HY-101572
    MHP

    Methyl caprooyl tyrosinate

    		 SphK Inflammation/Immunology Cancer
    MHP (Methyl caprooyl tyrosinate) is an activator of sphingosine kinase (SPHK1), and significantly stimulates CAMP mRNA and protein production. MHP (Methyl caprooyl tyrosinate) enhances antimicrobial defense and innate immunity .
    MHP
  • HY-12892
    SKI-178
    1 Publications Verification

    		 SphK Apoptosis Cancer
    SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC50 concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines .
    SKI-178
  • HY-12895
    SKI V
    1 Publications Verification

    		 SphK PI3K Apoptosis Cancer
    SKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC50 of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC50 of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity .
    SKI V
  • HY-101047S
    D-erythro-Sphingosine-d7
    1 Publications Verification

    Erythrosphingosine-d7; erythro-C18-sphingosine-d7; trans-4-Sphingenine-d7

    		 PKC Phosphatase Endogenous Metabolite Cancer
    D-erythro-Sphingosine-d7 is the deuterium labeled D-erythro-Sphingosine. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator .
    D-erythro-Sphingosine-d7
  • HY-19794
    MP-A08

    		SphK Cancer
    MP-A08 is a highly selective ATP competitive sphingosine kinase (SPHK1) inhibitor that targets both SphK1 and SphK2 with Ki values of 6.9 ± 0.8 μM and 27 ± 3 μM, respectively.
    MP-A08
  • HY-129099A
    N-Desmethyltamoxifen hydrochloride

    		PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite Cancer
    N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .
    N-Desmethyltamoxifen hydrochloride
  • HY-108391
    C8-Ceramide

    N-Octanoyl-D-erythro-sphingosine

    		 Apoptosis PKC Autophagy Inflammation/Immunology Cancer
    C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .
    C8-Ceramide
  • HY-117563
    CAY10621

    SKI 5C

    		 SphK Cancer
    CAY10621 (SKI 5C; compound 5c) is a specific sphingosine kinase 1 (SPHK1) inhibitor with an IC50 of 3.3 μM. CAY10621 is low toxic toward cells. CAY10621 has the potential for resistant cancer tumors research .
    CAY10621
  • HY-115735
    SKI-I

    		SphK Apoptosis Cancer
    SKI-I is a potent and selective inhibitor of human sphingosine kinase (SK), with an IC50 of 1.2 μM for ST-hSK. SKI-I also inhibits hERK2 (IC50=11 μM). SKI-I induces apoptosis in tumor cell lines .
    SKI-I
  • HY-124042
    K6PC-5
    4 Publications Verification

    		 SphK Filovirus Infection Neurological Disease Inflammation/Immunology
    K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research .
    K6PC-5
  • HY-130433
    NBD Sphingosine

    		Fluorescent Dye Others
    NBD Sphingosine (NBD-Sph), a fluorochrome, is a fluorescence-labeled sphingosine. NBD Sphingosine can be uesd for fluorescence assay for sphingosine kinases .
    NBD Sphingosine
  • HY-120268A
    SLM6031434 hydrochloride

    		SphK Inflammation/Immunology
    SLM6031434 hydrochloride is the hydrochloride salt form of SLM6031434 (HY-120268). SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .
    SLM6031434 hydrochloride
  • HY-101805
    SK1-IN-1
    2 Publications Verification

    		 SphK Inflammation/Immunology Cancer
    SK1-IN-1 is a potent sphingosine kinase 1 (SPHK1) inhibitor with an IC50 of 58 nM.
    SK1-IN-1
  • HY-147282
    Amgen-23

    		SphK Cancer
    Amgen-23 (compound 23) is a potent sphingosine kinases (SPHK) inhibitor with IC50 values of 20 nM and 1.6 μM for SPHK1 and SPHK2, respectively. Amgen-23 can be used for researching anticancer .
    Amgen-23
  • HY-162143
    SKI-349

    		SphK Akt mTOR Cancer
    SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells .
    SKI-349
  • HY-15425B
    PF-543 hydrochloride

    sphingosine Kinase 1 Inhibitor II hydrochloride

    		 SphK LPL Receptor Apoptosis Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    PF-543 hydrochloride (Sphingosine Kinase 1 Inhibitor II hydrochloride) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for SPHK1 over SPHK2. PF-543 hydrochloride is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 hydrochloride induces apoptosis, necrosis, and autophagy .
    PF-543 hydrochloride
  • HY-124863A
    (R)-AAL

    		SphK Inflammation/Immunology
    (R)-AAL is an immunomodulator. (R)-AAL decreases circulating T lymphocytes in rats, with an ID50 value of 0.009 mg/kg. (R)-AAL is a substrate of sphingosine kinase (SphK), which catalyzes the phosphorylation of (R)-AAL .
    (R)-AAL
  • HY-151351
    SphK2-IN-2

    		SphK Cancer
    SphK2-IN-2 (21g) is a potent and selective SphK2 inhibitor with an IC50 value of 0.23 μM .
    SphK2-IN-2
  • HY-129099
    N-Desmethyltamoxifen

    		PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite Cancer
    N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .
    N-Desmethyltamoxifen
  • HY-101047R
    D-erythro-Sphingosine (Standard)

    Erythrosphingosine (Standard); erythro-C18-sphingosine (Standard); trans-4-Sphingenine (Standard)

    		 Reference Standards PKC Phosphatase Endogenous Metabolite Cancer
    D-erythro-Sphingosine (Standard) is the analytical standard of D-erythro-Sphingosine. This product is intended for research and analytical applications. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4].
    D-erythro-Sphingosine (Standard)
  • HY-118442
    Sphingosine (d14:1)

    Tetradecasphing-4-enine

    		 PKC Cancer
    Sphingosine (d14:1) (Tetradecasphing-4-enine), a sphingolipid, is a potent Protein kinase C (PKC) inhibitor. Sphingosine (d14:1) prevents its interaction with sn-1,2-diacylglycerol (DAG)/Phorbol esters .
    Sphingosine (d14:1)
  • HY-120268
    SLM6031434

    		SphK Inflammation/Immunology
    SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .
    SLM6031434
  • HY-12005R
    Fingolimod hydrochloride (Standard)

    FTY720 (Standard)

    		 Reference Standards LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod (hydrochloride) (Standard) is the analytical standard of Fingolimod (hydrochloride). This product is intended for research and analytical applications. Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator .
    Fingolimod hydrochloride (Standard)
  • HY-112485
    (R)-FTY720-vinylphosphonate

    		SphK Drug Derivative Cancer
    (R)-FTY720-vinylphosphonate is a sphingosine kinase 1 (SK1) inhibitor. (R)-FTY720-ene-phosphonate is also an FTY720 analogue. (R)-FTY720-vinylphosphonate is promising for research of solid tumors like breast cancer .
    (R)-FTY720-vinylphosphonate
  • HY-16734
    Amiselimod

    MT-1303

    		 LPL Receptor Cardiovascular Disease Inflammation/Immunology
    Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases .
    Amiselimod
  • HY-119312
    C8 Dihydroceramide

    		PKC Cancer
    C8 Dihydroceramide is a negative control of C8 Ceramide. C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .
    C8 Dihydroceramide
  • HY-150513
    SLP9101555

    		SphK Cancer
    SLP9101555 (compound 14c) is a potent and selective SphK2 (sphingosine kinase 2) inhibitor (Ki=90 nM) with 200-fold selectivity over SphK1. SLP9101555 markedly decreases extracellular S1P (sphingosine 1-phosphate) levels .
    SLP9101555
  • HY-178992
    SphK1-IN-4

    		SphK Cancer
    SphK1-IN-4 (Compound 6b) is a sphingosine kinase 1 (SphK1) inhibitor. SphK1-IN-4 can be used for the research of cancer, such as lung cancer .
    SphK1-IN-4
  • HY-W019781
    Biotinylated sphingosine

    Biotinyl-Sph

    		 SphK Metabolic Disease
    Biotinylated sphingosine (Biotinyl-Sph) is a substrate of sphingosine kinase that can b used to detect the phosphorylation activity of sphingosine kinase 1 (SPHK1) and SPHK2 .
    Biotinylated sphingosine
  • HY-101047S1
    D-erythro-Sphingosine-13C2,d2

    Erythrosphingosine-13C2,d2; erythro-C18-sphingosine-13C2,d2; trans-4-Sphingenine-13C2,d2

    		 Isotope-Labeled Compounds PKC Endogenous Metabolite Phosphatase Cancer
    D-erythro-Sphingosine-13C2,d2 is a deuterated labeled D-erythro-Sphingosine . D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator .
    D-erythro-Sphingosine-13C2,d2
  • HY-16015A
    Opaganib hydrochloride

    ABC294640 hydrochloride

    		 SphK Cancer
    Opaganib (ABC294640) hydrochloride is a selective, competitive sphingosine kinase 2 (SK2) inhibitor with Ki of 9.8 μM.
    Opaganib hydrochloride
  • HY-16015R
    Opaganib (Standard)

    ABC294640 (Standard)

    		 SphK Reference Standards Cancer
    Opaganib (Standard) is the analytical standard of Opaganib. This product is intended for research and analytical applications. Opaganib (ABC294640) is a selective, competitive sphingosine kinase 2 (SK2) inhibitor with Ki of 9.8 μM.
    Opaganib (Standard)
  • HY-120152
    SLP7111228

    		SphK Interleukin Related TNF Receptor Cardiovascular Disease Inflammation/Immunology
    SLP7111228 is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 can be used in research related to neuroinflammatory diseases and pulmonary hypertension .
    SLP7111228
  • HY-148262
    SphK1-IN-3

    		SphK Cancer
    SphK1-IN-3 is an effective sphingosine kinase-1 (SphK1) inhibitor. SphK1-IN-3 inhibits SphK1 kinase activity with an IC50 value of 2.48 μM. SphK1-IN-3 can be used for the research of many diseases such as cancer, rheumatoid arthritis, diabetes, asthma, and pulmonary fibrosis .
    SphK1-IN-3
  • HY-162580
    SphK2-IN-3

    		SphK Cancer
    SphK2-IN-3 (compound 12q) is a selective active sphingosine kinase-2 inhibitor. SphK2-IN-3 has anti-proliferative activity against various cancer cells, inducing G2 phase arrest and apoptosis in liver cancer cells HepG2 .
    SphK2-IN-3
  • HY-12900
    RB-005

    		SphK Inflammation/Immunology Cancer
    RB-005 is a selective inhibitor of sphingosine kinase 1 (SK1) (IC50=3.6 µM), with weaker inhibition of another isoenzyme, SK2. The selective inhibition of RB-005 helps to distinguish the biological functions and roles of SK1 and SK2, which can be used in the study of inflammatory diseases and cancer .
    RB-005
  • HY-129099AR
    N-Desmethyltamoxifen hydrochloride (Standard)

    		Reference Standards PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite Cancer
    N-Desmethyltamoxifen (hydrochloride) (Standard) is the analytical standard of N-Desmethyltamoxifen (hydrochloride). This product is intended for research and analytical applications. N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].
    N-Desmethyltamoxifen hydrochloride (Standard)
  • HY-100008R
    Peretinoin (Standard)

    NIK333 (Standard)

    		 Reference Standards RAR/RXR SphK Autophagy HCV Infection Cancer
    Peretinoin (Standard) is the analytical standard of Peretinoin. This product is intended for research and analytical applications. Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1[1]. Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression[2]. Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM[3].
    Peretinoin (Standard)
  • HY-120152A
    SLP7111228 hydrochloride

    		SphK Interleukin Related TNF Receptor Cardiovascular Disease Inflammation/Immunology
    SLP7111228 hydrochloride is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 hydrochloride selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 hydrochloride decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 hydrochloride alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 hydrochloride can be used in research related to neuroinflammatory diseases and pulmonary hypertension .
    SLP7111228 hydrochloride
  • HY-108491S
    N,N-Dimethylsphingosine-13C2

    		Isotope-Labeled Compounds SphK Apoptosis Cancer
    N,N-Dimethylsphingosine- 13C2 is the 13C-labeled N,N-Dimethylsphingosine (HY-108491). N,N-Dimethylsphingosine is a sphingosine kinase inhibitor. N,N-Dimethylsphingosine binds competitively to sphingosine kinase and blocks the conversion of sphingosine to sphingosine-1-phosphate. N,N-Dimethylsphingosine inhibits sphingosine-1-phosphate release and aggregation of platelets, and also exerts pro-apoptotic effects by resetting ceramide/sphingosine-1-phosphate homeostasis. N,N-Dimethylsphingosine can be used in cancer-related research .
    N,N-Dimethylsphingosine-13C2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: